2 hours Q3 Earnings Estimate for RLMD Issued By Leerink PartnrsMarketBeat
Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) – Analysts at Leerink Partnrs dropped their Q3 2024 earnings estimates for Relmada Therapeutics in a research report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now antic…
Earnings · Nasdaq 100 · Science
X